Scholarlink

Background <p>Radiotherapy for malignant tumor treatment and irradiation (IR)-related diagnosis damage lymphocytes, which inevitably suppresses immunity and leads to unwanted clinical outcomes. However, a few agents have been approved by the Food and Drug Administration (FDA) to alleviate IR-induced injury. Here, the radioprotective effect and underlying mechanism of a new steroidal compound optimized from estradiol (E0703) were investigated.</p> Methods <p>Mice were exposed to γ-ray IR to establish an in vivo model of radiation injury, and human peripheral blood B lymphocytes (AHH-1) were employed to investigate injury in lymphocytes. Protein level changes in cell and tissue samples were detected by western blot and immunofluorescence. DNA damage was assessed by the comet assay and γH2AX staining. RNA sequencing was used to screen the critical genes mediating the radioprotective effect of E0703. To determine the direct target of E0703, cellular thermal shift (CETSA), drug affinity responsive target stability (DARTS), molecular docking, and surface plasmon resonance (SPR) assays were adopted. <i>GLI3</i> transactivation by estrogen receptor β (ERβ) was determined by the chromatin immunoprecipitation (ChIP) assay, while protein interactions were detected by coimmunoprecipitation (Co-IP). IP products were subjected to label-free proteomics assay to screen GLI3 conjugates.</p> Results <p>E0703 significantly improved survival and tissue injury in mice exposed to IR damage. In lymphocytes, IR-induced DNA damage was ameliorated with E0703 in an ataxia-telangiectasia mutated protein (ATM)-checkpoint kinase 2 (CHK2)-dependent manner. ERβ but not ERα was a direct target of E0703, wherein ERβ enhancement on the promoter region of <i>GLI3</i> triggered by E0703 could sustain its protein expression. The interaction between GLI3 and eIF4G1 favored by E0703 was critical for the formation of the eIF4F translation–initiation complex. eIF4F assembly was indispensable for the stimulation of ATM-CHK2 signaling involved in DNA damage repair.</p> Conclusions <p>E0703 alleviated IR-induced DNA damage in lymphocytes by selectively targeting ERβ. The formation of the eIF4F complex in a GLI3-dependent manner was critical for ATM-CHK2 activation triggered by E0703. Our study provides an alternative countermeasure to alleviate IR-induced lymphopenia in individuals undergoing radiotherapy or IR-related diagnosis.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

E0703 targets ERβ to facilitate the upregulation of GLI3, thereby alleviating irradiation-induced DNA damage on lymphocytes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Zebin Liao,
  • Liangliang Zhang,
  • Zekun Wu,
  • Changkun Hu,
  • Xianglin Tang,
  • Chengrong Xiao,
  • Liren Qian,
  • Yue Gao

摘要

Background

Radiotherapy for malignant tumor treatment and irradiation (IR)-related diagnosis damage lymphocytes, which inevitably suppresses immunity and leads to unwanted clinical outcomes. However, a few agents have been approved by the Food and Drug Administration (FDA) to alleviate IR-induced injury. Here, the radioprotective effect and underlying mechanism of a new steroidal compound optimized from estradiol (E0703) were investigated.

Methods

Mice were exposed to γ-ray IR to establish an in vivo model of radiation injury, and human peripheral blood B lymphocytes (AHH-1) were employed to investigate injury in lymphocytes. Protein level changes in cell and tissue samples were detected by western blot and immunofluorescence. DNA damage was assessed by the comet assay and γH2AX staining. RNA sequencing was used to screen the critical genes mediating the radioprotective effect of E0703. To determine the direct target of E0703, cellular thermal shift (CETSA), drug affinity responsive target stability (DARTS), molecular docking, and surface plasmon resonance (SPR) assays were adopted. GLI3 transactivation by estrogen receptor β (ERβ) was determined by the chromatin immunoprecipitation (ChIP) assay, while protein interactions were detected by coimmunoprecipitation (Co-IP). IP products were subjected to label-free proteomics assay to screen GLI3 conjugates.

Results

E0703 significantly improved survival and tissue injury in mice exposed to IR damage. In lymphocytes, IR-induced DNA damage was ameliorated with E0703 in an ataxia-telangiectasia mutated protein (ATM)-checkpoint kinase 2 (CHK2)-dependent manner. ERβ but not ERα was a direct target of E0703, wherein ERβ enhancement on the promoter region of GLI3 triggered by E0703 could sustain its protein expression. The interaction between GLI3 and eIF4G1 favored by E0703 was critical for the formation of the eIF4F translation–initiation complex. eIF4F assembly was indispensable for the stimulation of ATM-CHK2 signaling involved in DNA damage repair.

Conclusions

E0703 alleviated IR-induced DNA damage in lymphocytes by selectively targeting ERβ. The formation of the eIF4F complex in a GLI3-dependent manner was critical for ATM-CHK2 activation triggered by E0703. Our study provides an alternative countermeasure to alleviate IR-induced lymphopenia in individuals undergoing radiotherapy or IR-related diagnosis.

Graphical abstract